News

Akari Therapeutics Announces $12.75 Million Registered Direct Offering

NEW YORK and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing…

2 years ago

CanadaHelps Launches Small Charities Week and Unveils New Data Spotlighting the Challenges Facing Small Charities

Canadians called to action as rising inflation and growing demand for essential services place unprecedented strain on small charitiesTORONTO, Sept.…

2 years ago

Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial

- Hepion Collaborates with HepQuant and Summit Clinical Research to Evaluate Rencofilstat’s Impact on Hepatic Function and Numerous NASH Functional…

2 years ago

Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA

NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022FARMINGTON HILLS, Mich., Sept. 12, 2022 (GLOBE…

2 years ago

Healthcare Triangle to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022

PLEASANTON, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) announced today that Suresh Venkatachari, Chairman and…

2 years ago

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints –…

2 years ago

Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022

Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more…

2 years ago

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery…

2 years ago

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady…

2 years ago